- Home
- AMRN
as 05-09-2025 4:00pm EST
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
| Founded: | 1989 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 216.0M | IPO Year: | 1993 |
| Target Price: | $7.00 | AVG Volume (30 days): | 116.9K |
| Analyst Decision: | Sell | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.00 - $20.60 | Next Earning Date: | 05-07-2025 |
| Revenue: | $214,112,000 | Revenue Growth: | -22.83% |
| Revenue Growth (this year): | -21.73% | Revenue Growth (next year): | 0.89% |
Latest Amarin Corporation plc News
AMRN Breaking Stock News: Dive into AMRN Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y
Simply Wall St.
a day ago
Amarin First Quarter 2025 Earnings: Misses Expectations
GuruFocus.com
2 days ago
Amarin Corp PLC (AMRN) Q1 2025 Earnings Call Highlights: Strategic Global Expansion Amidst ...
Associated Press Finance
2 days ago
Amarin: Q1 Earnings Snapshot
GlobeNewswire
2 days ago
Amarin Reports First Quarter 2025 Financial Results
GuruFocus.com
7 days ago
Standex International Corp (SXI) Q3 2025 Earnings Call Highlights: Record Margins and Strategic ...
GlobeNewswire
10 days ago
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire
11 days ago
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
Compare AMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMRN Amarin Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.